Integrating Big Data, Patient Data, and Cost-Effectiveness into Clinical Practice: Promise and Prospects

First Plenary Session: Taking Stock of the Learning Health Care System: What Have We Achieved and Why Does It Matter?

Second Plenary Session: Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?

Third Plenary Session: Big Data, Big Systems, and Better Evidence: What Progress?
SATURDAY, MAY 16

ALL DAY COURSES 8:00AM-5:00PM

INTRODUCTION TO PHARMACOECONOMICS
Lorne Basskin, PharmD, Brown University
Incorporate pharmacoeconomics into study design and data analysis; collect and calculate costs of different alternatives; determine the economic impact of clinical outcomes; identify, track, and assign costs to health care resources.

BAYESIAN ANALYSIS – OVERVIEW AND APPLICATIONS
Christopher Hollenbeck, PhD, Penn State College of Medicine; David J. Vanness, PhD, University of Wisconsin Review the Bayesian approach and its applications to HEOR. Discuss basic elements of Bayesian statistics, classical statistics, and available statistical packages.

MORNING COURSES 8:00AM-12:00PM

INTRODUCTION TO DATABASE ANALYSIS OF OBSERVATIONAL STUDIES OF TREATMENT EFFECTS
Bradley Martin, PharmD, RPh, PhD, University of Arkansas for Medical Sciences Understand measurement of exposure and outcome, causal graphs, the use of stratification analysis before multivariable modeling, multivariable regression, propensity scoring, instrumental variable, and structural modeling techniques.

INTRODUCTION TO MODELING METHODS
Mark Roberts, MD, MPP, University of Pittsburgh Discuss principles and practice of decision analysis; construct decision trees; understand mechanisms of tree evaluation; acquire skills in interpreting published decision analyses.

INTRODUCTION TO PATIENT-REPORTED OUTCOMES
Andreas Pfeil, PhD and Charles Petrie, PhD, Pfizer Inc Learn methods for measuring quality of life, health status, and other types of health outcomes. Evaluate theoretical frameworks, reliability, validity, responsiveness, administration methods, respondent/administrative burdens, and issues of analysis and interpretation.

INTRODUCTION TO CONJUNCT ANALYSIS
A. Brett Hauber, PhD, RTI Health Solutions; Deborah Marshall, PhD, MPH, University of Calgary Discuss the conceptual basis for quantifying decision-maker preferences for medical interventions. Review design and analytical issues to obtain valid empirical preference estimates.

ELEMENTS OF PHARMACEUTICAL/BIOTECH PRICING I – INTRODUCTION
Jack Mycka and Renato Dellamano, PhD, MME LLC Learn key pricing terminology and issues. Know the tools to build and document product value, the role of pharmacoeconomics, and differences in payment systems.

AFTERNOON COURSES 1:00PM-5:00PM

META-ANALYSIS AND SYSTEMATIC REVIEWS IN COMPARATIVE EFFECTIVENESS RESEARCH
Joseph Cappelleri, PhD, MPH, Pfizer Inc.; Jeroen Jansen, PhD, Redwood Outcomes Analyze components of comparative effectiveness research, basic steps to quantitative systematic reviews, statistical methods of combining data, reporting results, and their usage.

UTILITY MEASURES
John Brazier, PhD, University of Sheffield; Brendan Mulhern, University of Technology Sydney Explore methods used to capture utilities. Discuss instruments to measure quality of life.

MODELING: DESIGN AND STRUCTURE OF A MODEL
Shelby Corman, PharmD, MS, BCPS, Pharmerit International; Mark S. Roberts, MD, MPP, University of Pittsburgh; Andrew Munzer, TreeAge Software, Inc. Review Markov and other modeling techniques. Learn practical steps in developing and using these models.

CASE STUDIES IN PHARMACOLOGICAL/BIOTECH PRICING II – ADVANCED
Jack M. Mycka and Renato Dellamano, PhD, MME LLC Explore new product pricing. Evaluate the business environment while integrating pricing, reimbursement, and pharmacoeconomic strategies with clinical development and marketing strategies.

SUNDAY, MAY 17

MORNING COURSES 8:00AM-12:00PM

DISCRETE EVENT SIMULATION FOR ECONOMIC ANALYSES – CONCEPTS
J. Jaime Caro, MDCM, FRCP, FACP and Jörgen Möller, MSc Mech Eng, Evidera Gain a basic understanding of the key concepts of discrete event simulation.

STATISTICAL METHODS IN ECONOMIC EVALUATIONS
Shelby Reed, PhD, RPh and Brad Hammill, MS, Duke Clinical Research Institute Discuss effect of distributional assumptions, univariate and multivariable analysis data, sample size and power calculations, and sampling uncertainty.

RISK-SHARING/PERFORMANCE-BASED ARRANGEMENTS FOR DRUGS AND OTHER MEDICAL PRODUCTS
Adrian Toove, MA, MPhil, Office of Health Economics; Lou Garrison, PhD and Josh Carlson, PhD, University of Washington Analyze theory and practice of these arrangements using examples from Europe, US, and Australia.

NEW! DEVELOPMENT OF CONCEPTUAL MODELS
Neil Hawkins, PhD, CStat, London School of Hygiene and Tropical Medicine; Elisabeth Fenwick, PhD, MSc, ICON Plc.; Beth Woods, MSc and Mark Sculpher, PhD, MSc, University of York Review important practical aspects of the development of conceptual models and gain an understanding of useful graphic tools for illustrating these concepts.

APPLICATIONS IN USING LARGE DATABASES
Diana Brixner, PhD, RPh and Joanne LaFleur, PharmD, MSPH, University of Utah; John Parkinson, PhD, CPRD; Michael Eddy, PhD, PharmD, Ycenda, LLC Discuss various databases, including how to access information and how researchers utilize the information.

PEATIENT-REPORTED OUTCOMES – ITEM RESPONSE THEORY
Bryce Reeve, PhD, University of North Carolina at Chapel Hill Review the basics of IRT models and their applications to improve health outcomes measurement.

USE OF INSTRUMENTAL VARIABLES IN OBSERVATIONAL STUDIES OF TREATMENT EFFECTS
Benjamin Craig, PhD, Moffitt Cancer Center; Bradley Martin, PharmD, RPh, PhD, University of Arkansas for Medical Sciences; Antoine El Khoury, PhD, MS, Johnson & Johnson Analyze sample selection models and their applications (two-stage least squares, intuition, RCTs). Engage in interactive exercises using STATA.

INTRODUCTION TO BUDGET IMPACT ANALYSIS: A 6-STEP APPROACH
C. Daniel Mullins, PhD, University of Maryland; Josephine Mauskopf, PhD and Stephanie Earnshaw, PhD, RTI Health Solutions Learn methods to determine cost-of-illness of a health condition and how to estimate the impact of new health care technologies.

AFTERNOON COURSES 1:00PM-5:00PM

NEW! INTRODUCTION TO BIG DATA ANALYSIS: GRAPH ANALYTICS
David R. Holmes III, PhD, Mayo Clinic College of Medicine Learn how graph analytics are used to deal with issues of data quality and completeness, the implications for the conclusions drawn, and where the challenges still lie.

BUDGET IMPACT ANALYSIS: APPLICATIONS & DESIGN ISSUES
Stephanie Earnshaw, PhD, MS, Anita Brogan, PhD, and Sorrel Wolowocz, PhD, RTI Health Solutions Engage in experimental learning opportunities focusing on key decision issues related to accuracy of budget impact estimation as well as applicability to decision makers.

DISCRETE EVENT SIMULATION FOR ECONOMIC ANALYSES – APPLICATIONS
J. Jaime Caro, MDCM, FRCP, FACP and Jörgen Möller, MSc Mech Eng, Evidera This course explores practical, hands-on discrete event simulation exercises using specific software.

NETWORK META-ANALYSIS
Joseph Cappelleri, PhD, MPH, Pfizer Inc.; Jeroen Jansen, PhD, Redwood Outcomes Understand fundamentals/concepts of network meta-analysis using WinBUGS case studies.

USE OF PROPENSITY SCORES IN OBSERVATIONAL STUDIES OF TREATMENT EFFECTS
John Seeger, PharmD, DrPh, Harvard Medical School/ Brigham and Women’s Hospital; Jeremy Rassen, ScD, Aetion, Inc Learn bias and methods for causal inference in observational studies and how propensity scores can reduce bias. Understand risk adjustment models, confounding, pros/cons of standard adjustment, and propensity scoring methodology.

ADVANCED DECISION MODELING FOR HEALTH ECONOMIC EVALUATIONS
Andrew Briggs, DPhil, MSc, University of Glasgow; Mark Sculpher, PhD, MSc, University of York Discuss decision modeling, making models probabilistic to capture parameter uncertainty, how to analyze and present results, and how to interpret and apply results.

NEW! USING MULTICRITERIA DECISION ANALYSIS IN HEALTH CARE DECISION MAKING: APPROACHES & APPLICATIONS
Maarten J. Ijzerman, PhD, University of Twente; Kevin Marsh, PhD, Evidera; Nancy Devlin, PhD, Office of Health Economics; Praveen Thokala, PhD, University of Sheffield Review the current MCA/MDA landscape, outline the best practices for conducting MCA, and discuss the steps involved in conducting MCA.

COMPLETE SHORT COURSE DESCRIPTIONS AVAILABLE AT WWW.ISPOR.ORG
Biosimilars on the Red Carpet: The Pharmacoeconomics of Their American Debut

This symposium will feature a multifaceted discussion of biosimilar drugs as they enter the U.S. marketplace in 2015. Speakers will address the U.S. regulatory environment, clinical and economic drivers of biosimilar uptake, pricing strategies, and other influential factors in payer decision making. (Sponsored by Proce)

6:30PM-7:30PM  EDUCATIONAL SYMPOSIAS

This symposium will discuss the relative affordability of new therapies for advanced cancers, current pricing models and their drawbacks, methods for innovation in pricing from new medicines in advanced cancers, and practical application of innovative pricing models. (Sponsored by GalbraithWight)

6:30PM-8:30PM  ISPOR STUDENT RESEARCH COMPETITION
8:30PM-9:30PM  ISPOR STUDENT & FACULTY ADVISOR RECEPTION

MONDAY, MAY 18

7:15AM-8:15AM  EDUCATIONAL SYMPOSIAS
Does Real World Evidence, in the Guise of Patient Registries, Add Any Value to the Decision-Making Process?

Real world evidence, such as large scale patient registries, have often been proposed as potential sources of clinical, economic, patient reported, and safety outcomes evidence that can aid decision making in health care. The impact on payer reimbursement decisions will be discussed. (Sponsored by ICON)

8:30AM-2:15PM  POSTERS - I
8:30AM-10:30AM  WELCOME & FIRST PLENARY SESSION
Taking Stock of the Learning Health Care System: What Have We Achieved and Why Does It Matter?

Nearly a decade ago, leaders envisioned a pathway to a learning health care system, where research is closely integrated and rapidly translated into practice by making use of electronic data that can track patients across health care providers and time. Since then, there has been substantial public and private investment to make this vision a reality. This session critically examines how far we have come and what the implications are for comparative effectiveness researchers, payers, patients, and the life sciences industry.

Moderator: Penny Mohr, MA, Senior Program Officer, Improving Healthcare Systems, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA
Speakers: Sarah Greene, MPH, Associate Director, CER Methods and Infrastructure, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Sachin H. Jain, MD, MBA, Chief Medical Officer, CareMore/Anthem and Lecturer in Health Care Policy, Harvard Medical School, Cerritos, CA, USA; Lewis G. Sandy, MD, FACP, Senior Vice President, Clinical Advancement, UnitedHealth Group, Minneapolis, MN, USA

10:30AM-11:00AM  BREAK, EXHIBITS & POSTERS - I
11:00AM-12:00PM  ISSUE PANELS - I

IP1: Should the Name of the Game be More “Skin in the Game”? The Scope and Consequences of Rx Cost-Shifting from Payers to Patients (Invited Issue Panel)

Moderator: Gerry Oster, PhD, Policy Analysis, Inc. and MINERVA Health Economics Network, Brookline, MA, USA
Panelists: Elizabeth Hargrave, MPA, University of Chicago, Chicago, IL, USA; Elise Gould, PhD, Economic Policy Institute, Washington, DC, USA; A. Mark Fendrick, MD, University of Michigan, Ann Arbor, MI, USA

IP2: Can We Afford Medical Breakthroughs for Large Prevalence Diseases? Lessons from Hepatitis C

Moderator: Dana P. Goldman, PhD, University of Southern California, Los Angeles, CA, USA
Panelists: Ross Maclean, MD, Precision Health Economics, Los Angeles, CA, USA; Tomas J. Philipson, PhD, University of Chicago, Chicago, IL, USA; Adrian Towse, MA, MPhil, Office of Health Economics (OHE), London, UK

IP3: Are We Comfortable Applying Existing Quality-Driven Adherence Measurement Methodologies to Specialty Pharmaceutical Products and What Are the Risks, Especially If Using Administrative Claims Databases?

Moderator: Craig Schilling, Pharm.D, Optum, Eden Prairie, MN, USA
Panelists: Richard Faris, PhD, MSc, RPh, UCB, Inc., Smyrna, GA, USA; Michael Ingham, MSc, Janssen Scientific Affairs, LLC, Horsham, PA, USA; Stephen M Lund, RPh, Senderra Rx Specialty Pharmacy, Richardson, TX, USA

IP4: What Is the Value of Big Data in Comparative Effectiveness Research and Clinical Decision Making?

Moderator: William H. Crown, PhD, Optum Labs, Cambridge, MA, USA
Panelists: Miguel Hernan, MD, DrPH, Harvard T. H. Chan School of Public Health, Boston, MA, USA; Sarah Greene, MPH, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Milton C Weinstein, PhD, Harvard T. H. Chan School of Public Health, Boston, MA, USA

IPS: PROs and Beyond: Are They Fit for Purpose to Improve Health Care Policy and Practice?

Moderator: Corinna Sorensen, MPH, MHSA, PhD, Avalere Health, Washington, DC, USA
Panelists: Kristi Mitchell, MPH, Avalere Health, Washington, DC, USA; Mark McClellan, MD, PhD, Brookings Institution, Washington, DC, USA; Sachin Kamal-Bahl, PhD, Pfizer, Philadelphia, PA, USA

12:00PM-2:15PM  LUNCH, EXHIBITS & POSTERS - I
12:15PM-1:15PM  EDUCATIONAL SYMPOSIAS
EQ-SD-5L: Development of the First National Tariffs

This symposium will discuss developments in EQ-SD-5L value sets programs and their use in supporting outcome-based studies. A value set approach and new value set for England will also be presented. A user perspective will be presented, together with an outline for future research. (Sponsored by EuroQol Research Foundation)

12:15PM-1:15PM  ISPOR STUDENT RESEARCH SHOWCASE
1:15PM-2:15PM  POSTER AUTHOR DISCUSSION HOUR - I
2:15PM-3:15PM  RESEARCH PODIUMS - I

CARDIOVASCULAR DISEASE RESEARCH STUDIES

CV1: Lifetime Health Care Costs of Obesity-Related Comorbidities in the United States, 2007-2010

CV2: The Association between Adherence to Cardiovascular Medications and Health Care Utilization

CV3: Prevalence and Direct Medical Costs Associated With Angina and Chest Pain Following Percutaneous Coronary Intervention in the United States

CV4: Outcomes and Health Resource Utilization among Patients with Heart Failure with Reduced Ejection Fraction (HFREF) at an Academic Medical Center (AMC) in the United States

RESEARCH ON DATABASE METHODS STUDIES

DB1: Critical Problems of Coding Data in Health Care: Obesity, Smoking, and Alcohol Use by Method of Measurement

DB2: A New Method for Counting Hemophilia-Related Bleeding Events in Claims Data

DB3: The Implications of Using a 30-, 60-, Or 90-Day Gap in Treatment to Specify Lines of Care in Gastric Cancer Treatment

DB4: Development and Validation of Algorithms to Identify Statin Intolerance in a US Administrative Database

HEALTH CARE MANAGEMENT STUDIES

HM1: Utilization of Antidiabetics after FDA Safety Announcements

HM2: Differences in Mastectomy Rates Based on Hormone Receptor Status in Early Stage Tumors: A SEER Database Analysis
HM4: How Much Evidence Do We Need before Implementing Pharmacogenomic Testing in the Clinic?

MEDICATION ADHERENCE STUDIES
MA1: Impact of a Pharmacist Medication Adherence Consultation Program on Health Care Costs and Risk of Hospitalization
MA2: Cost of Non-Adherence to Medication in a Post-MI Population
MA3: The Effect of Cost-Related Medication Nonadherence on the Decision of Taking Up Medicare Part D among Elderly Medicare Beneficiaries
MA4: Comprehensive Assessment of Patient Adherence to Drug Therapy: An Example Utilizing Real World Data for an Oral Multiple Sclerosis Treatment

MEDICAL DEVICE & DIAGNOSTIC RESEARCH STUDIES
MD1: Economic Evaluation of BST-CarGel as an Adjunct to Microfracture Versus Microfracture Alone in Knee Cartilage Surgery
MD2: Coverage Limits on Blood Glucose Test Strip Reimbursement for Diabetics in Canada: Utilization Impact for Diabetic Patients in the Ontario Public Drug Program (OPDP)
MD4: Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes

RESEARCH ON MODELING METHODS STUDIES
MO1: Reducing and Quantifying Over-Fitting in Regression Models
MO2: A Comparison of State Transition and Discrete Event Modeling Approaches for Antiplatelet Use in the Secondary Prevention of Thrombotic Events after Myocardial Infarction (MI)
MO3: Does the Use of Efficacy or Effectiveness Evidence in Cost-Effectiveness Analyses Matter?
MO4: Extrapolating All-Cause Mortality Estimates in Economic Evaluations: A Simulation Analysis

CANCER OUTCOMES RESEARCH STUDIES
CN1: The Impact of Chronic Conditions on the Economic Burden of Cancer Survivorship in the United States
CN2: A Comparative Cost Utility Analysis for First Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations
CN3: Synthesis of Multiple Types of Survival Data within a Weibull Proportional Hazards Meta-Analysis: Treatment Outcomes in Patients with Double Hit Lymphoma (DHL)
CN4: Reimbursement Decision Landscape for Metastatic Breast Cancer Therapies: A Comparison of Factors Leading to Favorable and Unfavorable Recommendations Across Leading HTA Agencies

CONCEPTUAL PAPERS
CP1: Methods to Assess the Association of Patient-Reported Outcomes and Clinical Endpoints
CP2: Interventions for Ultra-Rare Disorders (URDs) and the Logic of Cost Effectiveness
CP3: Life at a Premium: Considering an End-of-Life Premium in Value-Based Reimbursement
CP4: Guidance for the Conduct and Reporting of Modeling and Simulation in the Context of Health Technology Assessment

RESEARCH ON COST STUDIES METHODS
CS1: US Based Drug Cost Parameter Estimates Using National Average Drug Acquisition Cost
CS2: Economic Modelling in Randomized Controlled Trial (RCT)-Based Economic Evaluations: Empirical Examples of Its Effect on the Precision of Economic and Decision Outcomes
CS3: Cure Models: Accounting for Cured Patients in Economic Evaluations
CS4: A Review and Update to the Guidance Document for the Costing Process in the Canadian Health Care Setting

HEALTH CARE EXPENDITURE STUDIES
HE1: Health Care Resource Utilization among Medicare Beneficiaries with COPD: Comparison of High and Low Utilizers
HE2: Explaining the Excess Home Health Care Use and Expenditures among Elderly Medicare Beneficiaries with Parkinson’s Disease
HE3: Long-Term Health Care Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors
HE4: Optimizing Cancer Clinical Trials Research Investment Decisions in the United States: A Proof of Concept Portfolio Management Evaluation

HEALTH TECHNOLOGY ASSESSMENT STUDIES
HT1: Systematic Review of Cost Effectiveness of Ultra-Orphan Therapies: Lesson Learned from Published HTAs and Studies
HT2: Application of Cost-Effectiveness Logic to US Managed Care Drug Formularies: Long Term Outcomes of a Value-Based Formulary
HT3: Analysis of NICE Drug Technology Appraisals (2001-2014)
HT4: IQWiG Early Benefit Assessments of Type 2 Diabetes Therapies

PATIENT PREFERENCE STUDIES
PP1: Patients’ and Physicians’ Time Trade-Off Preferences for Adverse Outcomes Associated With Metastatic Colorectal Cancer Treatments
PP2: Patient Preferences for First-Line Maintenance Treatments for Ovarian Cancer
PP3: Patient Versus General Population Preferences in Anticoagulant Therapy
PP4: Measuring Treatment Preferences of Patients Diagnosed with Idiopathic Pulmonary Fibrosis Using Best-Worst Scaling

MEETING PROGRAM CONTINUED
IL, USA; Peter Wong, PhD, MS, MBA, RPh, HSPhS, Belleville, IL, USA; Kalyan S. Pasupathy, PhD, Mayo Clinic, Rochester, MN, USA

W7: Assessing Performance Outcome Measures for Regulatory Review: Conceptual and Methodological Challenges with Real World Examples Discussion Leaders: Rachel Simóné Ballinger, PhD, ICON, Oxford, UK; Elizabeth Nicki Bush, MHS, Eli Lilly, Indianapolis, IN, USA; Ashley Slagle, PhD, U.S. Food and Drug Administration, Silver Spring, MD, USA; Diana Rofail, PhD, Roche Products Limited, Welwyn Garden City, UK

6:00PM-7:45PM EXHIBITORS’ OPEN HOUSE RECEPTION & POSTERS - II

6:15PM-7:15PM ISPOR FORUMS - I


F3: Patient Engagement in Health Economic and Outcomes Research: Current and Future ISPOR Initiatives Presented by the ISPOR Patient-Centered Special Interest Group, European Patient Representative Roundtable, and ISPOR North American Patient Representative Roundtable

F4: From Cost-Effectiveness to Equity: Challenges Facing the Health Care System in Four Countries in Latin America Presented by the ISPOR Latin America Consortium

F5: Integrating Big Data into Real World Practice Presented by the ISPOR Student Council

F6: Synchronizing Information Chains with Health Systems Development for Better Outcomes Presented by the ISPOR BRICS

F7: Budget Impact Analysis of Epidemic Diseases across Africa Presented by the ISPOR Africa Network

7:15AM-8:15AM EDUCATIONAL SYMPOSIA

Leveraging Electronic Medical Records and Online Data for HEOR Research: Opportunities and Cautions This session will discuss recent advances in Electronic Medical Records (EMR) systems, analytical techniques, and software to mine new data sources for health economics and outcomes research (HEOR). Examples where nontraditional data sources have been utilized will be studied and potential issues of over-interpretation and over-reliance of data with suboptimal quality will be presented. (Sponsored by Analysis Group)

8:30AM-2:15PM POSTERS - III

8:30AM-10:30AM WELCOME & SECOND PLENARY SESSION

Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point? In recent years, both oncology and cardiology professional organizations have embraced the explicit consideration of cost-effectiveness and the value of treatments in developing and updating clinical practice guidelines and clinical pathways. This is a new development in the U.S. health care system, and one which is complicated by the pluralistic nature of the system. The impact that it could ultimately have on medical practice is not clear neither in terms of access to care and providers nor in terms of incentives for innovation. This session will explore the implications of this change for the range of stakeholders involved, including U.S. private insurers, clinicians, patients, and federal government programs.

Moderator: Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

Speakers: Mark A. Hlatky, MD, Professor of Health Research and Policy & Professor of Medicine (Cardiovascular Medicine), Stanford University School of Medicine, Stanford, CA, USA; Peter P. Yu, MD, FACP, FASCO, Director of Cancer Research, Palo Alto Medical Foundation, Sunnyvale, CA and President, American Society of Clinical Oncology (ASCO), Alexandria, VA, USA; Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

10:30AM-11:00AM BREAK, EXHIBITS & POSTERS - III

11:00AM-12:00PM ISSUE PANELS - II

IP6: How Should the FDA Regulate the Communication of Health Economic Data by Pharmaceutical Companies to Payers? Moderator: Peter J. Neumann, ScD, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Panelists: Laurie Burke, MPH, RPh, LORA Group, Royal Oak, MD, USA; Joseph Jackson, PhD, Health Outcomes Insights LLC, Lavallette, NJ, USA; Alan Bennett, JD, Ropes & Gray, Washington, DC, USA

IP7: New Models of Cancer Reimbursement: Are There Consequences for Spending and Patient Health? Moderator: Amitabh Chandra, PhD, Harvard University, Cambridge, MA, USA

Panelists: Andrew Briggs, DPhil, University of Glasgow, Glasgow, UK; Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA; Jennifer Malin, MD, PhD, Anthem, Woodland Hills, CA, USA

IP8: Challenges and Opportunities for Pragmatic Clinical Trials – Should Europe and the United States Approach Them Differently? Moderator: Rafael Alfonso-Cristancho, MD, PhD, MSc, GlaxoSmithKline (GSK), King of Prussia, PA, USA

Panelists: Bryan R Luce, PhD, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Tjeerd Van Staa, MD, PhD, MSc, University of Manchester, Manchester, UK

IP9: Continuous Patient Engagement: How Do We Partner with Patients Throughout the Research Life Cycle? Moderator: C. Daniel Mullins, PhD, University of Maryland School of Pharmacy, Baltimore, MD, USA

Panelists: Emil Chiauzzi, PhD, PatientsLikeMe, Cambridge, MA, USA; Daniel Frye, JD, NJ Commission for the Blind and Visually Impaired, Newark, NJ, USA; Marvin Mack, Center for Mind & Esteem Development, Baltimore, MD, USA


Panelists: Adrian Towsie, MA, MPH, Office of Health Economics, London, UK; Mark Trusheim, MS, Massachusetts Institute of Technology, Cambridge, MA, USA; Dan Ollendorf, PhD, Institute for Clinical and Economic Review, Boston, MA, USA

12:00PM-2:15PM LUNCH, EXHIBITS & POSTERS – III

12:15PM-1:15PM EDUCATIONAL SYMPOSIA

Dissemination of Health Economic Evidence to US Payers under FDAMA Section 114 – Lessons from the Past and New Guidance Expected Trends in sharing health economic information under Section 114 will be discussed. Perspectives of how pharmaceutical companies are handling the dissemination of health economic information as well as receipt of information by managed care will be shared and discussed in detail. (Sponsored by Xcenda)

1:15PM-2:15PM ISPOR ANNUAL BUSINESS MEETING

2:15PM-3:15PM ISSUE PANELS - III

IP11: The $2.6 Billion Question: Why Are Drug Development Costs Rising and Can We Afford It? (Invited Issue Panel) Moderator: Lou Garrison, PhD, Professor, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

Panelists: Joseph A. DiMasi, PhD, Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA; Patricia M. Danzon, PhD, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA; Adrian Towsie, MA, MPhil, Office of Health Economics, London, UK

IP12: Patient-Focused Drug Development: Are Policy Makers Listening? Moderator: John F P Bridges, PhD, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Panelists: Mark Walderhaug, AB, PhD, U.S. Food & Drug Administration, Silver Spring, MD, USA; Holly Peay, PhD, Parent Project Muscular Dystrophy, Hackensack, NJ, USA; Frank W Rockhold, PhD, GlaxoSmithKline, Cary, NC, USA
WEDNESDAY, MAY 20

7:15AM-8:15AM  EDUCATIONAL SYMPOSIA

Bridging the Real-World Evidence (RWE) Divide with Payers and IDNs: Making Pharma a True Collaborator in Evidence
This symposium will share results from pieces of research done with payers, academics, and pharma on how Real-World Evidence (RWE) has informed payer and Integrated Delivery Network (IDN) decisions to date, as well as other findings and case studies. Opportunities to accelerate engagement and impact of RWE and its generation will also be explored. (Sponsored by IMS Health)

8:30AM-2:45PM  POSTERS - V

8:30AM-9:30AM  ISSUE PANELS - IV

IP16: Do State Medicaid Formularies Worsen Outcomes for Patients with Mental Illness?
Moderator: Seth A. Seabury, PhD, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Panelists: Dana P. Goldman, PhD, University of Southern California, Los Angeles, CA, USA; Anupam B. Jena, MD, PhD, Harvard Medical School, Boston, MA, USA; Darius N. Lakdawalla, PhD, University of Southern California, Los Angeles, CA, USA

IP17: Value-Based Formulary Design (VBFD): Is Premera a Voice Crying in the Wilderness?
Moderator: Kathleen E. Hughes, MBA, Avalere Health LLC, Washington, DC, USA
Panelists: Dan Danielson, MS, RPh, Premera Blue Cross, Mountlake Terrace, WA, USA; Edmund J. Pazella, MD, MPH, Aetna, Inc., Hartford, CT, USA; John Graham, PharmD, GlaxoSmithKline, King of Prussia, PA, USA

IP18: Competitive Bidding for Therapeutically- Equivalent Brands
Moderator: Josephine A. Mauskopf, PhD, RTI Health Solutions, Research Triangle Park, NC, USA
Panelists: David W. Miller, PhD, Biogen Idec, Maidenhead, UK; Susan Hogue, PharmD, MPH, RTI International, Research Triangle Park, NC, USA

9:30AM-9:45AM  BREAK, EXHIBITS & POSTERS - V

9:45AM-11:00AM  WELCOME & THIRD PLENARY SESSION

Big Data, Big Systems, and Better Evidence: What Progress?
What could the growing interest in big data mean for health delivery systems and patients? This session will explore the challenges for incorporating big data into health system decisions and processes. A number of related questions will be explored. Can big data be used to improve evidence and clinical decision making? Is there a need for new analytical approaches? How will these developments affect patients?

Moderator: Adrian Towsie, MA, MPhil, Director, Office of Health Economics, London, UK

Speakers: Ari Caroline, Chief Analytics Officer, Memorial Sloan Kettering Cancer Center, New York, NY; Paul Wallace, MD, Chief Medical Officer & Senior Vice President, Clinical Translation, Optum Labs and Chair, Board of Directors, AcademyHealth, Cambridge, USA, MA

11:00AM-11:30AM  ISPOR 20th INTERNATIONAL MEETING RESEARCH PRESENTATION AWARDS

11:30AM-1:45PM  LUNCH, EXHIBITS & POSTERS - V

11:45AM-12:15PM  EDUCATIONAL SYMPOSIA

The Real World: How Integrated Data Is Used to Improve Patient Care
This symposium will focus on how integrated health information improves patient care. Speakers will discuss ways that access to actionable information can: 1) inform patients’ decision making; 2) support physicians’ treatment recommendations; and 3) achieve payers’ goal of aligned behaviors. (Sponsored by Optum)

12:45PM-1:45PM  POSTER AUTHOR DISCUSSION HOUR - V

1:45PM-2:45PM  WORKSHOPS - V

W22: How to Design an Analytic Strategy for Evidence Generation for Decision Makers
Discussion Leaders: Sean D. Sullivan, PhD, University of Washington, Seattle, WA, USA; Omar Dabbous, MD, MPH, GlaxoSmithKline, King of Prussia, PA, USA; Lou P Garrison, PhD, University of Washington, Seattle, WA, USA; Rafael Alfonso-Cristando, MD, PhD, MSc, GlaxoSmithKline (GSK), King of Prussia, PA, USA
W23: Integrated Longitudinal Data: How Dynamic Data Collection Can Bias Estimators and Possible Solutions
Discussion Leaders: Henry J. Henk, PhD, Optum, Eden Prairie, MN, USA; William H Olson, PhD, Janssen Scientific Affairs, LLC, Titusville, NJ, USA
W24: A Practical Approach to Understand the Concepts and Methods Used to Assess Heterogeneity and Inconsistency in Network Meta-Analyses
Discussion Leaders: Varun Ektare, MPH, Pharmacist International, Bethesda, MD, USA; Dipen Patel, PhD, Pharmacist International, Bethesda, MD, USA; Berhanu Alemayehu, PhD, AstraZeneca, Gaithersburg, MD, USA; Sonya J Snedecor, PhD, Pharmacist International, Bethesda, MD, USA
W25: Modeling Treatments for Rare Diseases: Methodologic Considerations, Challenges & Potential Solutions
Discussion Leaders: Michele Kohli, PhD, Optum, Burlington, ON, Canada; Debbie L. Becker, MSc, Optum, Burlington, ON, Canada; Milton C Weinstein, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Pablo Lapuerta, MD, Lexicon Pharmaceuticals, Princeton, NJ, USA
W26: Back to the Future: Learning the Lessons in Valuing EQ-5D-3L Health States
Discussion Leaders: Paul Kind, University of Leeds, Leeds, UK; Roisin Adams, PhD, National Centre for Pharmacoconomics, Dublin, Ireland; Mónica Viegas, PhD, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

2:45PM-3:00PM  BREAK & EXHIBITS - V

3:00PM-4:00PM  WORKSHOPS - V

W27: When Better Things Happen to a Good Model: A Development of the Difference in Differences (DD) Model into a Difference in Differences in Differences in Differences (DDDD) Model When Analyzing the Effect of an Intervention
Discussion Leaders: Junling Wang, PhD, The University of Tennessee College of Pharmacy, Memphis, TN, USA; Ya-Chen Tia Shih, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Yanru Qiao, MS, The University of Tennessee College of Pharmacy, Memphis, TN, USA
Discussion Leaders: Elise Berlinger, PhD, Agency for Healthcare Research and Quality, Rockville, MD, USA; Karen Schoelles, MD, SM, ECRI Institute, Plymouth Meeting, PA, USA; Marcus Lynch, PhD, ECRI Institute, Plymouth Meeting, PA, USA; Jalal A. Doshi, PhD, University of Pennsylvania, Philadelphia, PA, USA
W29: Strategies for Assessing the Patient-Level Economic Impact of Cancer Diagnosis
Discussion Leaders: Veena Shankaran, MD, MS, University of Washington, Seattle, WA, USA; Amy Davidoff, PhD, MS, Yale School of Public Health, New Haven, CT, USA; Representative from Interagency Consortium to Promote Health Economics Research on Cancer (HEROC)
W30: Warranthing Budget Predictability through Managed Entry Agreements and Insurance-Based Mechanisms
Discussion Leaders: Olivier Etienne, MSc, PhD, University of Liege, Liege, Belgium; Augustin Terlinden, MSc, BLUE ANTIDOTE, Tervuren, Belgium
W31: Developments and Communication Since the Issuance of FDA’s BLUE ANTIDOTE, Tervuren, Belgium
Discussion Leaders: Brooke Witherspoon, BA
W32: Integrated Longitudinal Data: How Dynamic Data Collection Can Bias Estimators and Possible Solutions
Discussion Leaders: Henry J. Henk, PhD, Optum, Eden Prairie, MN, USA; William H Olson, PhD, Janssen Scientific Affairs, LLC, Titusville, NJ, USA
W24: A Practical Approach to Understand the Concepts and Methods Used to Assess Heterogeneity and Inconsistency in Network Meta-Analyses
Discussion Leaders: Varun Ektare, MPH, Pharmacist International, Bethesda, MD, USA; Dipen Patel, PhD, Pharmacist International, Bethesda, MD, USA; Berhanu Alemayehu, PhD, AstraZeneca, Gaithersburg, MD, USA; Sonya J Snedecor, PhD, Pharmacist International, Bethesda, MD, USA
W25: Modeling Treatments for Rare Diseases: Methodologic Considerations, Challenges & Potential Solutions
Discussion Leaders: Michele Kohli, PhD, Optum, Burlington, ON, Canada; Debbie L. Becker, MSc, Optum, Burlington, ON, Canada; Milton C Weinstein, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Pablo Lapuerta, MD, Lexicon Pharmaceuticals, Princeton, NJ, USA
**WHY ATTEND ISPOR PHILADELPHIA?**

**What Does an ISPOR International Meeting Offer?**

ISPOR is recognized globally as the leading educational and scientific organization for outcomes research and its use in health care decisions. If you want to meet people in the health economics and outcomes research (HEOR) field, discuss the latest trends, and learn from the experts, attend ISPOR Philadelphia.

The ISPOR International meeting features three thought-provoking plenary sessions and more than 1,700 presentations in the form of workshops, issue panels and podium presentations plus posters on innovative research methods, health policy development using outcomes research, patient preferences, real-world data, clinical, economic, and patient-reported outcomes.

In addition, ISPOR offers a series of short (training) courses on trending topics in the HEOR field, from multi-criteria decision analysis to tried and true techniques in modeling, database, economic, preference-based, and outcomes research methodologies, as well as new courses such as Introduction to Big Data Analysis: Graph Analytics and Using Multi-Criteria Decision Analysis in Health Care Decision Making. Courses range from introductory to advanced and are taught by leading experts in the field, many with hands-on training opportunities!

**Who Attends?**

The ISPOR scope and sphere of influence includes outcomes researchers, health technology developers and assessors, regulators, health economists, health care policy makers, payers, providers, patients, populations, and society as a whole. The diversity in work environments and international scope of attendance provide excellent networking opportunities and stimulating discussions and debate.

**Why Attend?**

- Learn new & novel experiences in the conduct/use of HEOR.
- Stay current via cutting edge plenary sessions and presentations on innovative and controversial issues.
- Share research, ideas, and developments in the field and help advance the science.
- Network and renew connections with clients, colleagues or collaborators.

**A reflection on last year at ISPOR Montreal:**

ISPOR 19th Annual International Meeting, Montreal, Canada:

- Over 3,375 attendees
- 80 countries represented
- Over 1,700 presentations

"… this meeting has filled in many gaps in understanding [the] health outcomes and economics field and was a wonderful opportunity to network with colleagues and vendors alike." – ISPOR 19th Annual International Meeting attendee

Source: Online Meeting Evaluation

---

**REGISTRATION FEES  EARLY REGISTRATION DEADLINE: APRIL 14, 2015**

**PRE-MEETING SHORT COURSES**

<table>
<thead>
<tr>
<th>Course Type</th>
<th>THRU APRIL 14, 2015</th>
<th>AFTER APRIL 14, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Day Courses</td>
<td>Regular fee: $400</td>
<td>Student fee: $150</td>
</tr>
<tr>
<td></td>
<td>Student fee: $75</td>
<td>Student fee: $100</td>
</tr>
<tr>
<td>Morning/Afternoon Courses</td>
<td>Regular fee: $200</td>
<td>Student fee: $75</td>
</tr>
<tr>
<td></td>
<td>Student fee: $25</td>
<td>Student fee: $100</td>
</tr>
</tbody>
</table>

**MEETING REGISTRATION**

<table>
<thead>
<tr>
<th>Course Type</th>
<th>THRU APRIL 14, 2015</th>
<th>AFTER APRIL 14, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard</td>
<td>Member $700</td>
<td>Non-Member $850</td>
</tr>
<tr>
<td></td>
<td>Member $800</td>
<td>Non-Member $950</td>
</tr>
<tr>
<td>Clinical Practitioners (Clinical Practice, Hospital)</td>
<td>Member $500</td>
<td>Non-Member $650</td>
</tr>
<tr>
<td></td>
<td>Member $600</td>
<td>Non-Member $750</td>
</tr>
<tr>
<td>Full-Time Government and Academia</td>
<td>Member $400</td>
<td>Non-Member $550</td>
</tr>
<tr>
<td></td>
<td>Member $500</td>
<td>Non-Member $650</td>
</tr>
<tr>
<td>Patient Representative</td>
<td>Member $400</td>
<td>Non-Member $550</td>
</tr>
<tr>
<td></td>
<td>Member $500</td>
<td>Non-Member $650</td>
</tr>
<tr>
<td>Full-Time Students (must provide current enrollment docs)</td>
<td>Member $150</td>
<td>Non-Member $185</td>
</tr>
<tr>
<td></td>
<td>Member $200</td>
<td>Non-Member $235</td>
</tr>
<tr>
<td>One Day Registration (per day)</td>
<td>Member $375</td>
<td>Non-Member $525</td>
</tr>
<tr>
<td></td>
<td>Member $375</td>
<td>Non-Member $525</td>
</tr>
</tbody>
</table>

**MEETING ENHANCEMENTS**

- Short Course Continuing Education Accreditation (CPE & CME) Member $100  Non-Member* $100
- ISPOR Social Event: An evening of live music by the ISPOR Monte Carlos at the Hard Rock Café
  - Tues, May 19, 8:00PM-11:30PM
  - Member $65  Student $30

---

**VENUE INFORMATION/HOTEL RESERVATIONS**

**PHILADELPHIA MARRIOTT DOWNTOWN 1201 Market Street, Philadelphia, PA 19107 USA**

The Philadelphia Marriott Downtown is located in the heart of downtown Philadelphia and is approximately 10 miles (16 km) from the Philadelphia International Airport (PHL). It is easily accessible by car/taxi as well as by public transport.

**HOTEL RESERVATIONS**

**ISPOR Rates:** The discounted room rate for ISPOR Meeting attendees is $199 for single or double occupancy, plus applicable taxes in effect at the time of check-out (currently 15.2%) ISPOR delegate rates are subject to availability.

**Reservations:** Use the online booking link available at www.ispor.org >> 20th Annual International Meeting >> Attendee Information >> Hotel & Venue Information

**Cancellations or changes to reservations can be made without penalty up to 45 days prior to date of arrival, please see hotel terms & conditions.**

---

**MEETING PROMOTIONAL/EMPLOYMENT OPPORTUNITIES**

**EXHIBIT: SOLD OUT!**

**ADVERTISE:** Advertise in the Program & Schedule of Events! AD DEADLINE: MARCH 27, 2015

**SPONSOR:** Register now! Give your company increased visibility and prominence!

**eJOBS EMPLOYMENT CENTER:** Includes candidates’ database and interview room.

For more information: www.ispor.org

Register Online @ www.ispor.org